Planning a Scope Extension to 210 Pesticide Residues by LC-MS/MS
EnvAnalytika is a 22-person environmental and food testing laboratory, accredited since 2019 for 38 methods. Business development has signed a four-month supply contract with a retail chain for the determination of 210 pesticide residues in fresh produce, with a required limit of quantification of 0.01 mg/kg. The LC-MS/MS that will run the method is due to be installed in eight weeks. Only one analyst has LC-MS/MS experience, gained by self-training on a former employer's instrument. There is no certified reference material for 60 of the analytes, and the laboratory has participated in a single proficiency test round covering 12 analytes. The method is adapted from a published paper and has not been validated locally. The technical manager wants to skip a formal plan because validation is routine. The laboratory has no uncertainty procedure for multi-residue analysis.
1. Construct the implementation plan for this scope extension. List the workstreams, the acceptance gate for each and the clause basis, and state which activities can run in parallel and which cannot.
Read the worked answer
Workstream 1 - Contract and requirements. Gate: a signed technical review confirming that 0.01 mg/kg in these matrices is achievable and an agreed analyte list. Basis 7.1.1. Must precede everything because it fixes acceptance criteria.
Workstream 2 - Method and validation. Gate: a written validation plan with selectivity, linearity, LOD/LOQ, recovery, precision and matrix-effect criteria, then a validation report approved by an authorized person. Basis 7.2.1 and 7.2.2. Runs in parallel with equipment installation.
Workstream 3 - Equipment and environment. Gate: installation and operational qualification, calibration, column and gas-supply qualification, environmental conditions verified. Basis 6.4 and 6.3. Cannot be completed before delivery, so schedule validation runs after the instrument is qualified.
Workstream 4 - Personnel. Gate: a second analyst trained and authorized; the existing analyst formally authorized on this specific method. Basis 6.2. Run in parallel and start now, because it is the longest lead item after delivery.
Workstream 5 - Reference materials and traceability. Gate: certified reference materials from competent producers for as many analytes as possible, and a documented strategy for the 60 without them. Basis 6.5.3.
Workstream 6 - Quality control and external comparison. Gate: an internal QC scheme plus participation in a proficiency test or interlaboratory comparison for the new method. Basis 7.7.2 and 7.7.3.
Workstream 7 - Uncertainty. Gate: an uncertainty model built from validation and reference material data. Basis 7.6.
Workstream 8 - System integration. Gate: audit of the new process, management review, scope extension application. Basis 8.8, 8.9.
Dependencies: validation cannot be released before instrument qualification and analyst authorization; the extension application cannot be submitted before the validation report and uncertainty model exist.
2. Identify the five highest risks to a four-month go-live and define the go/no-go criteria you would put to the commercial director. What would you do if validation shows 15 of the 210 analytes failing the 0.01 mg/kg requirement?
Read the worked answer
Highest risks.
- Sixty analytes lack a certified reference material: accuracy may not be demonstrable, and the report will rest on spiking and recovery alone.
- Single trained analyst: one absence removes the capability, and the competence evidence is weak in an assessment.
- Instrument delivery or qualification slipping, which compresses validation into an unrealistic window.
- LOQ at 0.01 mg/kg for all 210 analytes may simply not be achievable for some compounds in some matrices.
- No proficiency test and no uncertainty model before go-live, so external validity and 7.6 are unsupported.
Go/no-go criteria. Go only if: the validation report demonstrates performance at the LOQ for the analyte list actually offered; two analysts are authorized; an interlaboratory comparison or proficiency test has been completed or is firmly booked; the uncertainty model is approved; the new process has been audited. Otherwise delay or reduce scope. State this in writing to the commercial director rather than in a corridor conversation, referencing 7.1.1, because the contract was signed before capability was confirmed.
If 15 analytes fail. Do not lower the LOQ silently and do not report them. Either exclude them from the offered scope and renegotiate with the retailer, or develop a second determinative step for those compounds. The scope extension application should list only what is validated; the contract must match the validated list.
3. The retail chain asks for accredited results from day one. Explain what the laboratory may and may not state on reports before and after the scope extension, and how this affects the contract and the accreditation application.
Read the worked answer
Before the extension is granted. Results for the new method may be issued, but not as accredited. The report must not carry the accreditation symbol and must make the accreditation status clear for those analyses. Stating or implying accreditation for a method outside the granted scope is a false claim and a breach of the accreditation agreement, independently of ISO/IEC 17025.
After the grant. The symbol and accreditation statement may be used only for the parameters and matrices actually listed in the granted scope. If the extension is partial, the report must distinguish accredited from non-accredited results, and results from any external provider must be clearly identified.
Contract handling. The clause requiring accredited results from day one is not deliverable. The laboratory should amend it to a staged arrangement: non-accredited reporting with a defined date for the extension, and a fallback if the extension is delayed or partial. Signing a contract for a capability that does not yet exist repeats the 7.1.1 failure that created this problem.
Application handling. Submit the extension only when validation, uncertainty, competence and quality-control evidence exist, and align the timing with the assessment cycle. Assessors will ask to see the first reports issued for the new method; if those reports already claim accreditation, the finding will be about misrepresentation rather than about technical performance.